Loading…
Cytek Biosciences, Inc. is projected to rise to $4.46 by 2027, a +6% move from its current price of $4.22. CTKB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $4.14 | $4.22 | $4.31 | +0.03% |
| Aug 3 | $4.11 | $4.22 | $4.34 | +0.07% |
| Aug 4 | $4.08 | $4.22 | $4.37 | +0.10% |
| Aug 5 | $4.06 | $4.23 | $4.40 | +0.13% |
| Aug 6 | $4.04 | $4.23 | $4.42 | +0.16% |
| Aug 7 | $4.03 | $4.23 | $4.44 | +0.20% |
| Aug 8 | $4.01 | $4.23 | $4.46 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.01 | $4.23 | $4.46 | +0.23% |
| Week 2 | $3.94 | $4.24 | $4.56 | +0.46% |
| Week 3 | $3.88 | $4.25 | $4.65 | +0.69% |
| Week 4 | $3.84 | $4.26 | $4.73 | +0.93% |
| Week 5 | $3.80 | $4.27 | $4.80 | +1.16% |
| Week 6 | $3.77 | $4.28 | $4.86 | +1.39% |
| Week 7 | $3.74 | $4.29 | $4.92 | +1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytek Biosciences, Inc. is a cell analysis solutions company that provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations.
It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc.
in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Cytek Biosciences, Inc. (CTKB) is classified in Healthcare and operates as a cell analysis solutions provider. The current price is $4.46 with a market capitalization of $575.98M, and the company holds the 2801st rank by market cap.
The price outlook shown in the forecast indicates a progressive path higher from 2026 through 2050, with a 2050 average of $35.82 and a 2050 maximum of $61.05, reflecting a bullish long‑term trajectory. The near term includes a 2026 average of $4.46, a 2027 average of $4.97, and steady gains toward higher long‑term levels.
A major floor 21.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.7% below — buyers have tended to step in here.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key CTKB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTKB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.36 | Sell | $4.34 | Sell |
| MA 10 | $4.45 | Sell | $4.41 | Sell |
| MA 20 | $4.52 | Sell | $4.44 | Sell |
| MA 50 | $4.29 | Sell | $4.38 | Sell |
| MA 100 | $4.34 | Sell | $4.38 | Sell |
| MA 200 | $4.57 | Sell | $4.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.72 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -200.20 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -9.25 | Sell |
| Bollinger %B (20,2) | -0.13 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 25.40 | Buy |
| Momentum (10) | -0.40 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.28 | Sell |
| ADX (14) | 12.61 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is Neutral with RSI(14) at 50.0. The price action is hovering around the SMA50 of $4.20, while the SMA200 sits at $4.56, suggesting a balance between near-term momentum and longer-term trend.
The current 30-day range is $3.87 to $5.14, indicating a relatively wide band for short-term moves. The stock faces resistance at $4.65 and support at $3.77, framing a cautious near-term setup as it navigates these levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.36 | $4.22 | $5.39 | 0% | Neutral | |
| $3.65 | $4.46 | $5.71 | +6% | Neutral | |
| $4.25 | $5.30 | $6.97 | +26% | Bullish | |
| $5.08 | $6.44 | $8.67 | +53% | Bullish | |
| $5.13 | $6.60 | $9.05 | +56% | Bullish | |
| $5.43 | $7.07 | $9.86 | +68% | Bullish | |
| $5.60 | $7.38 | $10.44 | +75% | Bullish | |
| $5.59 | $7.45 | $10.67 | +76% | Bullish | |
| $6.39 | $8.60 | $12.49 | +104% | Bullish | |
| $7.06 | $9.61 | $14.10 | +128% | Bullish | |
| $8.93 | $12.70 | $19.57 | +201% | Bullish | |
| $17.22 | $26.37 | $43.68 | +525% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.36 | $4.22 | $5.14 | +0.00% |
| September 2026 | $3.66 | $4.30 | $5.16 | +1.85% |
| October 2026 | $3.69 | $4.35 | $5.26 | +1.18% |
| November 2026 | $3.76 | $4.46 | $5.43 | +2.47% |
| December 2026 | $3.70 | $4.40 | $5.39 | -1.30% |
Click any year to see its month-by-month CTKB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cytek Biosciences, Inc.'s 2026 outlook centres on $4.22, within a $3.36 to $5.39 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTKB could reach as high as $5.71, with a base case around $4.46 and support toward $3.65 — roughly +6% from $4.22. Price action looks broadly range-bound.
Expect CTKB to range from $4.25 to $6.97 through 2028. The $5.30 average target implies a +26% move from current prices. That is up +19% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CTKB price prediction for 2029 points to an average of $6.44 (low $5.08, high $8.67) — a potential gain of +53% on today's $4.22. Momentum favours further upside here.
In 2030, CTKB is projected to trade between $5.13 and $9.05, averaging $6.60 — a potential gain of +56% from today's $4.22. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cytek Biosciences, Inc.'s 2031 outlook centres on $7.07, within a $5.43 to $9.86 range. That is up +7% on the projected 2030 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2032, CTKB could reach as high as $10.44, with a base case around $7.38 and support toward $5.60 — roughly +75% from $4.22. Buyers look set to stay in control over this stretch.
Expect CTKB to range from $5.59 to $10.67 through 2033. The $7.45 average target implies a +76% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The CTKB price prediction for 2034 points to an average of $8.60 (low $6.39, high $12.49) — a potential gain of +104% on today's $4.22. Buyers look set to stay in control over this stretch.
In 2035, CTKB is projected to trade between $7.06 and $14.10, averaging $9.61 — a potential gain of +128% from today's $4.22. That is up +12% on the projected 2034 average. Momentum favours further upside here.
Cytek Biosciences, Inc.'s 2040 outlook centres on $12.70, within a $8.93 to $19.57 range. That is up +32% on the projected 2035 average. That marks a +201% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTKB could reach as high as $43.68, with a base case around $26.37 and support toward $17.22 — roughly +525% from $4.22. Momentum favours further upside here.
Investing $1,000 in CTKB today (≈ 236.966825 CTKB) could be worth
$6,249.6
+$5,249.6 (+525%) by 2050 · US Dollar
Based on the average projected CTKB price of $26.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTKBwould be worth at today's price.
$1,000 invested in CTKB on Jul 31, 2025 (≈ 277.777785 CTKB) would be worth
$1,172.22
+$172.22 (+17.2%) today · 1.17× · US Dollar
Based on a CTKB entry price of $3.6 vs. today's $4.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.46 | $946.19 | -5.4% |
| 1 month ago | $4.58 | $921.4 | -7.9% |
| 3 months ago | $4.62 | $913.42 | -8.7% |
| 6 months ago | $5.16 | $817.83 | -18.2% |
| 1 year ago | $3.6 | $1,172.22 | +17.2% |
| All time (5.0y) ago | $23.91 | $176.5 | -82.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTKB forecast.
Our base-case forecast reaches $8.40 around 2034.
Implied market cap at $8.40: $1.08B
The multi-year forecast paints a bullish long‑term path for Cytek Biosciences. In 2026 the average price is projected at $4.46 with a max of $5.77 and a min of $3.36, representing an initial foothold before sustained appreciation.
By 2030 the average is $7.77 with a min of $5.97 and a max of $10.82, yielding a 74.3% ROI and a bullish sentiment. The trajectory continues to 2040, where the average rises to $16.92 and the max to $26.71, with a 279.4% ROI. By 2050 the average reaches $35.82 and the max $61.05, delivering a 703.1% ROI and a bullish outlook.
The forecast also shows intermediate years (e.g., 2031–2035) with rising averages and double‑digit ROI, indicating sustained upside potential but also acknowledging that these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $7.77, min $5.97, max $10.82; ROI 74.3%; sentiment BULLISH.
Forecast shows bullish sentiment across 2027–2050 with increasing averages and ROI up to 703.1% by 2050; however, these are estimates and not guarantees.
The 2050 forecast max is $61.05, implying a potential around that level by 2050, with an average of $35.82.
Current price is $4.46; market cap is $575.98M.
Avg $16.92; min $11.62; max $26.71; ROI 279.4%; sentiment BULLISH.
Cytek Biosciences, Inc. Community Discussion
0Share your Cytek Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.